Q-omics provides the consensus-scored HEATR9 profile across patient tissues and cancer cell-line models. HEATR9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HEATR9 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, HEATR9 RNA expression shows 14,934 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where HEATR9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HEATR9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HEATR9 survival associations across molecular data types. HEATR9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HEATR9 RNA expression–survival associations across cancer types. High HEATR9 expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, CESC, SKCM and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HEATR9 RNA expression.
This table summarizes HEATR9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HEATR9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HEATR9 shows higher tumor expression in KIRC, STAD, BLCA, LIHC, READ and CHOL. The KIRC box plot shows higher HEATR9 RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p < 0.001).
This table shows molecular features associated with HEATR9 in patient tissues and cancer cell lines. In patient samples, HEATR9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HEATR9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
